Heart drug camzyos may do more than clear Blockages—New study investigates
NCT ID NCT07120776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the heart medication Camzyos (Mavacamten) can improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM). Researchers will use special PET-CT scans to measure blood flow before and after 12 months of treatment. Up to 75 adults with HOCM who are already starting Camzyos as part of their routine care will take part. The goal is to see if the drug helps reduce chest pain and shortness of breath by improving oxygen supply to the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Camzyos (Mavacamten)
What this could lead to
If successful, this could show that Camzyos not only relieves obstruction but also improves blood supply to the heart, potentially guiding better treatment for HOCM.
What could go wrong
This is a small, early-stage observational study (75 people) that does not test the drug itself—it only observes effects. Results may not apply to all patients, and the drug's known side effects include heart-related risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY \(HOCM\) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester University NHS Foundation Trust
RECRUITINGManchester, M13 9WL, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••